Cylex

Cylex was a life science diagnostic company and a leader in the development and manufacture of unique products that monitor the immune system for predicting and managing human health. It was the first and only company to offer a patent-protected, FDA-cleared cellular assay of immune system function, ImmuKnow, to measure the vitality of a patient’s immune system from a single drop of blood. The company’s products enabled physicians to better manage and personalize the treatment of organ transplant patients as well as emerging applications across an array of life-threatening diseases, such as HIV, HCV, cancer, diabetes, and autoimmune disorders. Cylex operated in a relatively new segment of diagnostics, measuring specific cellular responses to assess the immune system’s health or response to therapy. For example, in transplantation, Cylex’s products allowed physicians to monitor patients’ immune system status, providing an additional layer of information to traditional diagnostic measures, such as therapeutic drug levels, cell counts, or the occurrence of negative outcomes such as organ rejection or infection. Cylex was acquired by Viracor-IBT Laboratories Inc. in 2013.